Sherwin-Williams
SHW
$339.74
-0.03%
The Sherwin-Williams Company is the largest global manufacturer of paints and coatings, developing, producing, and distributing architectural paint, industrial coatings, and related products through three segments: a company-owned Paint Stores network of more than 4,800 locations serving professional contractors, a Consumer Brands group supplying branded paint to big-box retailers such as Lowe's, and a Performance Coatings group providing specialized finishes for automotive refinishing, packaging, and industrial wood applications. Its competitive identity rests on the vertically integrated, company-controlled distribution model of the Paint Stores Group, which gives it unmatched specification control with professional painters and pricing power that pure manufacturers cannot replicate, complemented by a dividend aristocrat profile (47 consecutive years of increases). The current investor narrative centers on a mid-cycle housing and renovation recovery: after a multi-year volume trough driven by weak existing-home turnover and deferred repainting demand, the company has returned to positive year-over-year revenue growth (up 7.89% in the September 2026 quarter) while defending industry-leading margins, and the debate now hinges on whether contractor demand inflects further into 2027 or stalls alongside a soft macro backdrop. A secondary thread is capital allocation — aggressive buybacks (roughly $520 million in Q3 alone) and bolt-on acquisitions funded by strong free cash flow, against a leveraged balance sheet that bulls view as manageable and bears flag as a constraint if the recovery disappoints.…
SHW
Sherwin-Williams
$339.74
Related headlines
Investment Opinion: Should I buy SHW Today?
Rating: Hold (accumulate on weakness). The core thesis is that Sherwin-Williams is a high-quality franchise — 48.9% gross margin, 55.9% ROE, $3.078 billion trailing free cash flow, and a 47-year dividend-increase streak — whose 7.89% revenue re-acceleration is real, but whose 31.2x trailing / 26.5x forward PE already discounts most of the recovery, leaving only +7.0% upside to the $374.25 consensus target against a realistic -17% to -30% downside. The 15 Buy / 14 Hold / 0 Sell split with a 2.07 recommendation score captures this tension precisely: the Street likes the asset but not the entry price.
Supporting evidence is genuinely strong on quality and cash generation but mixed on momentum. Revenue grew 7.89% year over year to $6.86 billion in Q3 2026, up sequentially from $5.667 billion in Q1 and $6.789 billion in Q2, confirming a real painting-season recovery. Free cash flow of $3.078 billion comfortably covers the $194 million quarterly dividend (payout ratio 30.7%, yield 0.99%) and funded $520 million of Q3 buybacks, shrinking diluted shares from 254.1 million in Q4 2024 to 242.8 million in Q3 2026. However, gross margin compressed roughly 140 basis points sequentially to 47.77% from 49.17%, net margin slipped to 11.97% from 13.10% a year ago, and the 26.5x forward multiple on $17.74 consensus EPS sits at a 70-100% premium to the 15-18x PE typical of coatings peers — a premium that requires margin stabilization, not just revenue growth, to hold.
Three risks could invalidate the thesis: continued gross margin erosion below 47% (Q3 already showed the 140bp sequential decline), a stall in contractor-driven Paint Stores volume given roughly 59% revenue concentration in that segment, and balance-sheet constraints from 2.81x debt-to-equity and a 0.868 current ratio with interest expense up to $139 million per quarter from $117 million. This Hold would upgrade to Buy if gross margin recovers above 49% while revenue growth holds near 8%, or if the shares pull back toward the $315-$320 consolidation shelf (roughly 10% downside) improving the risk/reward; it would downgrade to Sell if gross margin breaks below 47% and consensus EPS of $17.74 starts getting cut. Verdict: fairly valued to modestly rich relative to its own low-20s trough multiple and to peers — a quality compounder priced for a recovery that has begun but not yet proven operating leverage.
Sign up to view all
SHW 12-Month Price Forecast
Sherwin-Williams is a premier franchise in the early innings of a cyclical recovery, with revenue growth of 7.89% and $3.078 billion of trailing free cash flow confirming the trough is behind it, but the stock's 31.2x trailing and 26.5x forward earnings already price much of that recovery in. The critical unresolved question is margin: gross margin fell 140 basis points sequentially to 47.77% even as revenue accelerated, meaning operating leverage has not yet materialized, and until it does the premium multiple is vulnerable. Analyst sentiment is cautiously constructive — 15 Buy, 14 Hold, zero Sell, $374.25 average target — but the modest +7.0% implied upside and the tight $329-$420 range suggest the Street is waiting for Q4 results and 2027 guidance before repositioning. I would upgrade to bullish if gross margin recovers above 49% with revenue growth sustained near 8%, and downgrade to bearish if margin breaks below 47% and consensus EPS of $17.74 begins to be cut. With a beta of 1.053 and a -21.36% max drawdown over the past year, position sizing should account for a realistic -17% to -30% downside if the recovery disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Sherwin-Williams's 12-month outlook, with a consensus price target around $373.83 and implied upside of +10.0% versus the current price.
Average Target
$373.83
29 analysts
Implied Upside
+10.0%
vs. current price
Analyst Count
29
covering this stock
Price Range
$329 - $420
Analyst target range
Coverage is broad and engaged, with 24 analysts publishing ratings: 15 Buy, 14 Hold, and zero Sell, yielding a consensus recommendation of "buy" (mean score 2.07 on a scale where lower is more bullish). The average target price of $374.25 implies approximately +7.0% upside from the current $349.89, a modest but positive signal that suggests the Street sees the stock as fairly valued with room for modest appreciation rather than deeply undervalued. The consensus leans cautiously bullish — the absence of any Sell ratings is notable, but the near-even Buy/Hold split indicates genuine debate about the pace of the housing-led recovery and margin trajectory.
The target range of $329.00 to $420.00 is moderately wide (roughly 28% from low to high), signaling meaningful dispersion in assumptions. The $420 high target likely assumes a full contractor-demand recovery, gross margin re-expansion toward the 49%+ level, and multiple expansion back toward the high end of the historical band, while the $329 low target — only about 6% below the current price — prices in margin compression and a stalled volume recovery without a severe downside case. Recent institutional actions show stability rather than momentum: RBC Capital, Citigroup, JP Morgan, DA Davidson, and Guggenheim all reiterated Buy/Outperform/Overweight ratings in late October 2026, while UBS and Barclays maintained Neutral/Equal Weight, and there were no upgrades or downgrades in the visible record. The tight clustering of reiterations around the Q3 print suggests analysts are waiting for the next data point — likely Q4 results or 2027 guidance — before repositioning, and the modest implied upside to consensus means the stock's near-term return will depend more on execution against the $17.74 consensus EPS than on multiple expansion.
Bulls vs Bears: SHW Investment Factors
The bull case currently holds the stronger evidence: revenue growth has inflected to 7.89%, free cash flow of $3.078 billion is funding aggressive buybacks, and the analyst consensus is a Buy with zero Sell ratings and a $374.25 target. However, the bear case is not weak — gross margin has compressed roughly 140 basis points sequentially to 47.77%, the balance sheet carries 2.81x debt-to-equity with a sub-1.0 current ratio, and the 31.2x trailing PE embeds a full recovery that has yet to translate into operating leverage. The single most important tension is whether contractor-driven Paint Stores volume can re-accelerate enough to restore gross margin above 48-49% and justify the premium multiple, or whether the recovery stalls and the stock de-rates toward its low-20s historical trough multiple. Resolution of that margin-versus-volume question — most likely visible in Q4 results and 2027 guidance — will determine whether the modest +7% analyst upside expands or the 25-30% downside scenario gains credibility.
Bullish
- Revenue growth inflecting to 7.89%: Q3 2026 revenue of $6.86 billion grew 7.89% year over year versus $6.358 billion in Q3 2025, a clear acceleration from the near-flat sequential comparisons of the prior year. The sequential build from $5.667 billion in Q1 to $6.789 billion in Q2 to $6.86 billion in Q3 confirms the painting-season recovery is real rather than price-only.
- Analyst consensus buy, no sells: Of 24 analysts, 15 rate Buy and 14 Hold with zero Sell ratings, yielding a consensus score of 2.07 and an average target of $374.25, roughly +7.0% above the $349.89 price. The absence of any Sell rating despite a near-even Buy/Hold split signals the Street sees downside as limited even while debating the pace of recovery.
- Elite margins and 55.9% ROE: Gross margin of 48.9%, operating margin of 16.1%, and ROE of 55.86% are far superior to the roughly 15-18x PE / 9-11x EBITDA specialty chemicals peer set. The company-owned store network underpins pricing power that supports these structurally higher margins through the cycle.
- Strong free cash flow funds buybacks: Trailing free cash flow of $3.078 billion comfortably covers the $194 million quarterly dividend and funded $520 million of Q3 buybacks, with Q3 FCF of $976 million and Q2 of $1.239 billion. Share count has shrunk from 254.1 million diluted in Q4 2024 to 242.8 million in Q3 2026, compounding per-share value.
Bearish
- Gross margin compressing 140bp sequentially: Gross margin fell from 49.17% in Q2 2026 to 47.77% in Q3, down from 49.16% a year earlier, and net margin slipped to 11.97% from 13.10%. The recovery is being purchased with margin give-back, so operating leverage has yet to show up despite accelerating revenue.
- Leveraged balance sheet, thin liquidity: Debt-to-equity stands at 2.81x with a current ratio of just 0.868, and quarterly interest expense has climbed to $139 million from $117 million a year ago, leaving interest coverage of roughly 8.6x. ROE of 55.86% is flattered by an equity multiplier near 6.8x, while ROA of only 9.48% reveals the true asset intensity.
- Premium valuation leaves no room for error: At 31.2x trailing and 26.5x forward earnings, plus 20.6x EV/EBITDA and 3.39x sales, SHW trades at a roughly 70-100% premium to the 15-18x PE and 9-11x EBITDA typical of coatings peers. A reversion to the low-20s multiple seen in 2023-2024 would imply roughly 25-30% downside.
- Modest analyst upside, split conviction: The $374.25 average target implies only +7.0% upside, and the near-even 15 Buy / 14 Hold split shows genuine debate rather than conviction. The $329 low target sits just 6% below the current price, meaning even the bear case prices in only a mild stall, not a severe downside scenario.
SHW Technical Analysis
SHW is in a choppy but constructive recovery trend rather than a clean uptrend: the stock is up just 3.26% over the past year and 6.73% year-to-date, but sits at $349.89, which is approximately 68% of its 52-week range of $289.86 to $377.77 — closer to the upper half but still about 7.4% below the 52-week high. That positioning implies the stock has repaired most of its prior drawdown (max drawdown of -21.36% over the period) without becoming overextended, leaving room to challenge the highs if momentum holds. The 180-day price series confirms the pattern: a May trough near $293 gave way to a July–August rally peaking at $369.73, followed by a September–October consolidation in the $315–$345 zone before a November push back toward $363.50.
Short-term momentum is clearly accelerating and diverging positively from the longer-term trend. The stock gained 7.81% over the past month versus a 2.56% decline over three months, producing a relative strength versus SPY of +10.07 percentage points for the one-month window — a sharp reversal from the -9.01 points of relative weakness over the trailing year. The six-month change of +16.59% (versus SPY's +2.13%) shows the recovery has real breadth, and the November move from $332.61 on October 30 to an intra-period high of $363.50 on November 4 occurred on visibly heavier volume days, suggesting institutional accumulation rather than a low-conviction bounce. The one-month/one-year divergence is best read as a mean-reversion rally off a depressed base rather than a trend reversal signal, though the failure to hold the $363.50 spike (closing at $349.89) warrants monitoring.
Key technical levels are well defined: support sits at the 52-week low of $289.86, with a secondary shelf around $315–$320 where the stock consolidated through September and October; resistance is the 52-week high of $377.77, roughly 8% above the current price. A decisive breakout above $377.77 would confirm the recovery as a new leg higher and likely trigger momentum-driven buying, while a breakdown below $315 would invalidate the November advance and refocus attention on the $290 floor. With a beta of 1.053, SHW carries essentially market-level volatility — only about 5% more volatile than SPY — so position sizing need not be discounted heavily for systematic risk, but the 3.63 short ratio and cyclical end-market exposure mean idiosyncratic drawdowns (the -21.36% max drawdown is a reminder) can still be sharp.
Beta
1.05
1.05x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$290-$378
Price range past year
Annual Return
+3.6%
Cumulative gain past year
| Period | SHW Return | S&P 500 |
|---|---|---|
| 1m | +0.7% | -9.7% |
| 3m | -2.0% | -9.9% |
| 6m | +9.9% | -7.5% |
| 1y | +3.6% | +4.7% |
| ytd | +3.6% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SHW Fundamental Analysis
Revenue is re-accelerating after a prolonged trough. Q3 2026 revenue of $6.86 billion grew 7.89% year over year versus $6.358 billion in Q3 2025, and the sequential cadence — $5.667 billion in Q1, $6.789 billion in Q2, $6.86 billion in Q3 — shows steady build through the painting season. The segment mix explains the trajectory: the Paint Stores Group generated $4.016 billion (roughly 59% of sales) and is the growth engine tied to contractor demand, Consumer Brands contributed $937 million and remains the drag from soft DIY and big-box channel dynamics, and Performance Coatings added $1.903 billion with industrial end-market exposure. The 7.89% growth rate marks a clear inflection from the prior-year comparisons (Q3 2025 revenue of $6.358 billion was up only modestly from $6.315 billion in Q2 2025), supporting the thesis that the volume recovery is real rather than price-only.
Profitability remains robust but is compressing at the margin. Q3 2026 net income was $821 million on a 47.77% gross margin, down from $833 million and a 49.16% gross margin in Q3 2025, and gross margin has drifted from 49.17% in Q2 2026 to 47.77% in Q3 — a roughly 140 basis point sequential decline that suggests raw material or mix pressure. Operating margin followed the same path, falling from 18.13% in Q2 2026 to 17.53% in Q3 and 18.44% in the year-ago quarter, while net margin slipped to 11.97% from 13.10% a year earlier. The company remains solidly profitable with a 10.90% trailing net margin and 16.14% operating margin, but the direction of travel — margin give-back despite accelerating revenue — implies the recovery is being purchased with promotional or cost absorption, and investors will want to see gross margin stabilize above 48% to validate operating leverage.
Cash generation is strong but the balance sheet is the key risk. Trailing free cash flow is $3.078 billion, with Q3 2026 FCF of $976 million and Q2 of $1.239 billion, comfortably covering the $194 million quarterly dividend and funding $520 million of Q3 buybacks; however, Q1 2026 FCF was effectively zero ($0.8 million) due to working capital seasonality, highlighting the lumpiness of cash flow. Debt-to-equity stands at 2.81x with a current ratio of 0.868, and interest expense has climbed to $139 million per quarter from $117 million a year ago, consuming a meaningful share of operating income (interest coverage of roughly 8.6x). ROE of 55.86% is exceptional but heavily flattered by leverage (equity multiplier near 6.8x), while ROA of just 9.48% reveals the true asset intensity of the business — the company generates ample cash internally but its capital structure leaves limited cushion if the cyclical recovery reverses.
Quarterly Revenue
$6.9B
2026-09
Revenue YoY Growth
+7.9%
YoY Comparison
Gross Margin
47.8%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SHW Overvalued?
Because Sherwin-Williams is solidly profitable (Q3 2026 net income of $821 million), the PE ratio is the appropriate primary metric. The stock trades at 31.2x trailing earnings and 26.5x forward earnings (on consensus EPS of $17.74), and the roughly 15% compression from trailing to forward multiple implies the market expects meaningful earnings growth — consistent with the recovery narrative — though the PEG ratio of -11.11 is distorted by a negative growth base and should be disregarded. On EV/EBITDA of 20.6x and price-to-sales of 3.39x, the stock is priced as a high-quality compounder rather than a cyclical chemical company.
Relative to the specialty chemicals industry, SHW commands a substantial premium: its 31.2x trailing PE and 20.6x EV/EBITDA sit well above the roughly 15–18x PE and 9–11x EBITDA multiples typical of commodity and specialty coatings peers, a premium of roughly 70–100% on earnings. That gap is defensible on quality grounds — a 48.9% gross margin, 16.1% operating margin, 55.9% ROE, and the moat of the company-owned store network are far superior to the sector average — but it leaves little room for error if growth decelerates. The 17.4x price-to-book ratio is extreme in absolute terms, though it reflects the asset-light store model and buyback-driven equity shrinkage rather than speculative excess.
Historically, SHW's own valuation band has been wide: trailing PE ranged from roughly 19x to 44x over the past several years, with the stock trading at 41.8x at year-end 2025 and 23.7x as recently as Q3 2026 in the historical ratios data. At 31.2x trailing and 26.5x forward, the stock sits in the middle-to-upper portion of its own range — not cheap versus its 2023–2024 trough multiples in the low-20s, but well below the 40x+ peaks seen during earnings troughs. The market is pricing in a successful cyclical recovery with margin stabilization; a return to the low-20s multiple would imply roughly 25–30% downside, while a re-rating toward the high-30s would require evidence of sustained double-digit EPS growth.
PE
31.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~56x
vs. Industry Avg
31.4x
Industry PE ~31.4x*
EV/EBITDA
20.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on a leveraged balance sheet and margin erosion during a cyclical recovery. Debt-to-equity of 2.81x and a current ratio of 0.868 leave limited liquidity cushion, while quarterly interest expense has risen to $139 million from $117 million a year ago, consuming a meaningful share of operating income at roughly 8.6x coverage. Gross margin fell from 49.17% in Q2 2026 to 47.77% in Q3, and net margin slipped to 11.97% from 13.10% a year earlier, meaning the 7.89% revenue growth is being achieved without operating leverage. Cash flow is also lumpy — Q1 2026 free cash flow was effectively zero ($0.8 million) due to working capital seasonality — so a demand stall would strain the dividend-plus-buyback program that depends on $3.078 billion of trailing FCF.
Market and competitive risks stem from a premium valuation that assumes a successful recovery. At 31.2x trailing and 26.5x forward earnings, 20.6x EV/EBITDA, and 3.39x sales, SHW trades at roughly a 70-100% premium to the 15-18x PE and 9-11x EBITDA of specialty coatings peers, leaving little room for error if growth decelerates. The Consumer Brands segment ($937 million in Q3) remains a drag from soft DIY and big-box channel dynamics, and the Paint Stores Group's roughly 59% revenue concentration ties the thesis to contractor and housing turnover. With a beta of 1.053 the stock carries essentially market-level systematic risk, but the -21.36% max drawdown and 3.63 short ratio show idiosyncratic drawdowns can still be sharp, and recent market commentary around geopolitical tensions and Fed uncertainty highlights how quickly cyclical multiples can compress.
In a worst-case scenario, a stalled housing and renovation recovery would combine with continued gross margin compression below 47%, forcing analysts to cut the $17.74 consensus EPS and re-rate the stock toward its low-20s historical trough multiple. That chain — volume stall, margin give-back, EPS cuts, multiple compression — would take the shares toward the $289.86 52-week low, roughly -17% from the current $349.89, and a full reversion to the low-20s PE on trailing earnings would imply closer to -25% to -30%. The analyst low target of $329.00, only about 6% below the current price, understates this tail because it prices a mild stall rather than a severe one. An investor should therefore size the position for a realistic -17% to -30% downside if the recovery disappoints.
FAQ
Ranked by severity, the first risk is margin erosion: gross margin fell from 49.17% in Q2 2026 to 47.77% in Q3 and net margin slipped to 11.97% from 13.10% a year earlier, meaning the 7.89% revenue growth is arriving without operating leverage — a break below 47% would likely force cuts to the $17.74 consensus EPS. Second is valuation compression: at 26.5x forward earnings versus 15-18x for peers, a de-rating toward the low-20s multiple would cost 25-30%. Third is balance-sheet and cyclical exposure: debt-to-equity of 2.81x, a current ratio of 0.868, and interest expense up to $139 million per quarter limit flexibility, while roughly 59% of revenue sits in the contractor-dependent Paint Stores segment tied to housing turnover. Fourth is relative performance and drawdown risk: SHW is up just 3.26% over the past year versus SPY's +12.27% (-9.01 points of relative weakness) and has suffered a -21.36% max drawdown, showing that idiosyncratic losses can be sharp despite a market-level beta of 1.053.
The 12-month scenario framework assigns 55% to a base case of $365-$380, 25% to a bear case of $290-$329, and 20% to a bull case of $400-$420. The base case is most likely: revenue grows high-single digits, gross margin stabilizes in the 47.5-48.5% band without full re-expansion, and EPS lands near the $17.74 consensus, supporting the $374.25 average target — roughly +7% from $349.89 — with the multiple holding in the high-20s to low-30s. The bear case assumes a stalled housing recovery plus gross margin below 47%, forcing EPS cuts and a re-rate toward the $329 analyst low and ultimately the $289.86 52-week low. The bull case requires a full contractor-led recovery, gross margin back above 49%, and multiple expansion toward the high-30s on forward EPS above consensus, reaching the $420 high target. The key assumption behind the base case is that margin stabilizes rather than re-expands — the recovery continues, but operating leverage remains elusive.
SHW screens as fairly valued to modestly rich. At 31.2x trailing and 26.5x forward earnings, 20.6x EV/EBITDA, and 3.39x sales, it trades at roughly a 70-100% premium to the 15-18x PE and 9-11x EBITDA typical of specialty coatings peers. That premium is partly earned by superior economics — 48.9% gross margin and 16.1% operating margin versus a commodity-leaning peer set — but it leaves little cushion. Against its own history the stock sits in the middle-to-upper part of a wide 19x-44x trailing PE band, well below the 41.8x at year-end 2025 but above the low-20s trough multiples of 2023-2024. The 17.4x price-to-book is extreme in absolute terms, though it reflects the asset-light store model and buyback-driven equity shrinkage rather than speculative excess. The market is effectively pricing a successful recovery with margin stabilization; a return to the low-20s multiple would imply 25-30% downside, while a re-rating toward the high-30s would require evidence of sustained double-digit EPS growth.
From a risk/reward perspective, SHW is a reasonable but not compelling entry at $349.89. The upside to the $374.25 average analyst target is only about +7.0%, while the downside to the $289.86 52-week low is roughly -17%, and a reversion to the low-20s PE seen in 2023-2024 would imply -25% to -30%. The quality case is genuine — 48.9% gross margin, 55.9% ROE, $3.078 billion of trailing free cash flow, and 15 Buy versus 0 Sell ratings — but the 26.5x forward PE on $17.74 consensus EPS already embeds much of the recovery. It is a better buy for patient, long-horizon investors who can tolerate cyclical drawdowns (the -21.36% max drawdown is a reminder) and who accumulate on weakness toward the $315-$320 shelf rather than chasing the November spike to $363.50. It would become a clearer buy if gross margin recovers above 49% with revenue growth near 8%, or if the price pulls back roughly 10% to improve the risk/reward.
SHW is better suited to long-term holding than short-term trading. It is a mid-cycle cyclical compounder with a market-level beta of 1.053, a modest 0.99% dividend yield backed by a 47-year increase streak, and earnings visibility anchored by a company-owned store network and roughly $29.4 billion of consensus 2027 revenue. The stock's path is choppy rather than trending — up 3.26% over one year, 6.73% year-to-date, and 16.59% over six months, with a -21.36% max drawdown — so short-term traders face whipsaw risk around quarterly prints and housing data. Earnings visibility is decent but not high, since results hinge on contractor demand and margin trajectory that can shift quarter to quarter, as the 140bp sequential gross margin decline showed. A concrete minimum holding period of 18-24 months is appropriate, allowing time for the housing and renovation recovery to translate into operating leverage and for the premium multiple to be validated by EPS growth rather than multiple expansion.

